Irisin is regulated by car in liver and is a mediator of hepatic glucose and lipid metabolism

Molecular Endocrinology

Volumn 30, Issue 5, 2016, Pages 533-542

  Mo, Li ^a   Shen, Jing ^a   Liu, Qinhui ^a   Zhang, Yuwei ^a   Kuang, Jiangying ^a   Pu, Shiyun ^a   Cheng, Shihai ^a   Zou, Min ^a   Jiang, Wei ^a   Jiang, Changtao ^b   Qu, Aijuan ^c   He, Jinhan ^a  

^a SICHUAN UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA CYANOPREGNENOLONE; ADENOSINE PHOSPHATE; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLIC AMP; CYCLOPHILIN; FIBRONECTIN TYPE III DOMAIN CONTAINING PROTEIN 5; GLUCOSE; HEPATIC GLUCOSE; IRISIN; LIPID; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; CELL RECEPTOR; FIBRONECTIN; FNDC5 PROTEIN, MOUSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ADENOVIRIDAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOGENESIS; LIVER; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; ADIPOCYTE; ANIMAL; C57BL MOUSE; METABOLISM; MOUSE MUTANT; NUCLEAR REACTOR; PHYSIOLOGY;

ADENOSINE MONOPHOSPHATE; ADIPOCYTES; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIET, HIGH-FAT; FIBRONECTINS; GLUCONEOGENESIS; GLUCOSE; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MICE, TRANSGENIC; NUCLEAR REACTORS; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER;

EID: 84964801945     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1292     Document Type: Article

References (34)

1. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009; 49: 306-317.
2. He J, Lee JH, Febbraio M, Xie W. The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp Biol Med (Maywood). 2011; 236: 1116-1121.
3. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des. 2010; 16: 1941-1951.
4. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-γ-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481: 463-468.
5. Timmons JA, Baar K, Davidsen PK, Atherton PJ. Is irisin a human exercise gene? Nature. 2012; 488: E9-E10; discussion E10-E11.
6. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNAexpression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61: 1725-1738.
7. Hecksteden A, Wegmann M, Steffen A, et al. Irisin and exercise training in humans-results from a randomized controlled training trial. BMC Med. 2013; 11: 235.
8. Jedrychowski MP, Wrann CD, Paulo JA, et al. Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab. 2015; 22: 734-740.
9. Aydin S, Kuloglu T, Aydin S, et al. A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides. 2014; 61: 130-136.
10. Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013; 59: 557-562.
11. Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS. Irisin in patients with nonalcoholic fatty liver disease. Metabolism. 2014; 63: 207-217.
12. Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013; 27: 365-369.
13. Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013; 100: 96-101.
14. Xie W, Yeuh MF, Radominska-Pandya A, et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA. 2003; 100: 4150-4155.
15. Uppal H, Toma D, Saini SP, Ren S, Jones TJ, Xie W. Combined loss of orphan receptors PXR andCARheightens sensitivity to toxic bile acids in mice. Hepatology. 2005; 41: 168-176.
16. Stedman CA, Liddle C, Coulter SA, et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci USA. 2005; 102: 2063-2068.
17. Gao J, Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci. 2012; 33: 552-558.
18. Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature. 2000; 407: 920-923.
19. Gao J, He J, Zhai Y, Wada T, Xie W. The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J Biol Chem. 2009; 284: 25984-25992.
20. Dong B, Saha PK, Huang W, et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci USA. 2009; 106: 18831-18836.
21. He J, Gao J, Xu M, et al. PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes. 2013; 62: 1876-1887.
22. Wang T, Shah YM, Matsubara T, et al. Control of steroid 21-oic acid synthesis by peroxisome proliferator-activated receptor γ and role of the hypothalamic-pituitary-adrenal axis. J Biol Chem. 2010; 285: 7670-7685.
23. Liu MJ, Takahashi Y, Wada T, et al. The aldo-keto reductase Akr1b7 gene is a common transcriptional target of xenobiotic receptors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2009; 76: 604-611.
24. Hedbacker K, Birsoy K, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab. 2010; 11: 11-22.
25. He J, Nishida S, Xu M, Makishima M, Xie W. PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts. Gastroenterology. 2011; 140: 2095-2106.
26. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98: E769-E778.
27. Spruiell K, Jones DZ, Cullen JM, Awumey EM, Gonzalez FJ, Gyamfi MA. Role of human pregnane X receptor in high fat dietinduced obesity in pre-menopausal female mice. Biochem Pharmacol. 2014; 89: 399-412.
28. Spruiell K, Richardson RM, Cullen JM, Awumey EM, Gonzalez FJ, Gyamfi MA. Role of pregnane X receptor in obesity and glucose homeostasis in male mice. J Biol Chem. 2014; 289: 3244-3261.
29. Spruiell K, Jones DZ, Cullen JM, Awumey EM, Gonzalez FJ, Gyamfi MA 2014 Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice. Biochem Pharmacol. 2014; 89: 399-412.
30. Park MJ, Kim DI, Choi JH, Heo YR, Park SH. New role of irisin in hepatocytes: the protective effect of hepatic steatosis in vitro. Cell Signal. 2015; 27: 1831-1839.
31. Zhang Y, Li R, Meng Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes. 2014; 63: 514-525.
32. Song H, WuF, Zhang Y, et al. Irisin promotes human umbilical vein endothelial cell proliferation through the ERK signaling pathway and partly suppresses high glucose-induced apoptosis. PLoS One. 2014; 9: e110273.
33. Krishan S, Richardson DR, Sahni S. Adenosine monophosphateactivated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Mol Pharmacol. 2015; 87: 363-377.
34. Lee HJ, Lee JO, Kim N, et al. Irisin, a novel myokine, regulates glucose uptake in skeletal muscle cells via AMPK. Mol Endocrinol. 2015; 29: 873-881.